Informations:
Erreur:
ID
34599
Description
Evaluation of Dapagliflozin Taken Twice-daily; ODM derived from: https://clinicaltrials.gov/show/NCT01217892
Lien
https://clinicaltrials.gov/show/NCT01217892
Mots-clés
Versions (1)
- 19/01/2019 19/01/2019 -
Détendeur de droits
see on clinicaltrials.gov
Téléchargé le
19 janvier 2019
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Type 2 Diabetes NCT01217892
Eligibility Type 2 Diabetes NCT01217892
- StudyEvent: Eligibility
Similar models
Eligibility Type 2 Diabetes NCT01217892
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
ID.1
Item
provision of informed consent prior to any study specific procedures
boolean
ID.2
Item
diagnosis of t2dm
boolean
ID.3
Item
current antihyperglycaemic treatment with metformin immediate release formulation monotherapy >/= 1500 mg/day at a stable dose for at least 10 weeks prior to enrolment. other treatment with oads within the 10 weeks prior to enrolment is not permitted.
boolean
ID.4
Item
hba1c ≥ 6.7% and ≤10.5%, based on central laboratory values from screening visit, and enrolment visit 1.
boolean
ID.5
Item
diagnosis of type 1 diabetes mellitus, known diagnosis of maturity onset diabetes of the young (mody) or secondary causes of diabetes mellitus
boolean
ID.6
Item
history of diabetic ketoacidosis
boolean
ID.7
Item
symptoms of poorly controlled diabetes including, but not limited to, marked polyuria, polydipsia, and/or greater than 10% weight loss during the 3 months prior to enrolment
boolean
ID.8
Item
fpg >270 mg/dl (>15.0 mmol/l)
boolean
ID.9
Item
bmi >45 kg/m2
boolean